The programmed cell death protein 1 inhibitors can ameliorate the disease course but no superior effect to those of other reported immunosuppressive treatments were observed.[38,39] The malignant potential of ganglioneuroblastoma lies between that of neuroblastomas and ganglioneuromas.[19] Chemotherapy should be considered based on the pathological subtype. The gene discussed is PDCD1; the disease is neuroblastoma.